<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25511640</article-id><article-id pub-id-type="pmc">4300407</article-id><article-id pub-id-type="publisher-id">260</article-id><article-id pub-id-type="doi">10.1007/s40261-014-0260-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kishimoto</surname><given-names>Miyako</given-names></name><address><phone>+81-3-3202-7181</phone><email>miyakok@fides.dti.ne.jp</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Noda</surname><given-names>Mitsuhiko</given-names></name><address><email>mnoda@hosp.ncgm.go.jp</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655 Japan </aff><aff id="Aff2"><label/>Diabetes and Metabolism Information Center, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan </aff><aff id="Aff3"><label/>Department of Diabetes Research, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>35</volume><fpage>141</fpage><lpage>147</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><p>The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an &#x003b1;-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients with type 2 diabetes. Baseline data were collected on day 1. Miglitol was administered on days 2 and 3. On day 4, miglitol and anagliptin were coadministered before breakfast. On days 1, 3, and 5, blood was drawn for plasma glucose, serum C-peptide, plasma glucagon, total and active glucagon-like peptide-1 (GLP-1), and total and active glucose-dependent insulinotropic peptide (GIP) measurements. Coadministration of anagliptin with miglitol resulted in additional improvements in glycemic control over the entire day in three of the four patients. The C-peptide, glucagon, and total and active GLP-1 and GIP responded differently to the medications for each patient, suggesting interindividual differences in hormonal responses, which may be complicated by multifactorial effects.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s40261-014-0260-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d30e202"><title>Key Points</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Administration of miglitol to four patients with type 2 diabetes receiving ongoing insulin treatment showed beneficial effects on postprandial hyperglycemia.</td></tr><tr><td align="left">Based on the continuous glucose monitoring results, the coadministration of anagliptin with miglitol resulted in additional improvements in glycemic control in three of the patients.</td></tr><tr><td align="left">C-peptide, glucagon, and total and active glucagon-like peptide-1 and glucose-dependent insulinotropic peptide responded differently to the study medications for each patient.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Dipeptidyl peptidase-4 (DPP-4) inhibitors, by inhibiting DPP-4 enzymatic activity, increase active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels and improve hyperglycemia in a glucose-dependent manner by increasing serum insulin and decreasing serum glucagon levels in diabetic patients [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Alpha-glucosidase inhibitors (a-GIs), another type of oral antidiabetic drug, also attenuate postprandial blood glucose fluctuations by delaying the absorption of digested carbohydrates from the small intestine [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Considering the different mechanisms of DPP-4 inhibitors and &#x003b1;-GIs, their use in combination therapy is promising for improving glycemic control [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The present case study aimed at examining the efficacy, through the use of a continuous glucose monitoring system (CGMS) [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>] and hormone measurements, of a DPP-4 inhibitor (anagliptin) [<xref ref-type="bibr" rid="CR15">15</xref>], and an &#x003b1;-GI (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus.</p></sec><sec id="Sec2"><title>Case Presentation and Intervention</title><p>The baseline characteristics of the four Japanese inpatients with type 2 diabetes in this study are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The study protocol was approved by the Ethics Committee of the National Center for Global Health and Medicine (NCGM), and written informed consent was obtained from each subject. The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and Guidelines for Good Pharmacoepidemiology Practice. All patients were admitted to the diabetes ward at the NCGM and equipped with a CGMS device (Medtronic MiniMed, CGMS-GOLD, Minneapolis, MN, USA). Prior to study initiation, oral medications that might affect the results of the study, such as &#x003b1;-GIs or glinides, were discontinued for at least 5&#x000a0;days. A once-daily injection of insulin glargine was continued for all patients throughout the study without changing the dosage and timing of injections (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The first blood samples, as for baseline data, were collected on day 1. Subsequently, miglitol (50&#x000a0;mg three times a day, just before each meal) was administered on days 2 and 3. On days 4 and 5, anagliptin (100&#x000a0;mg/day) was given before breakfast, in addition to miglitol. Blood samples were collected on the first, third, and fifth days of the study. Measurements of plasma glucose, serum C-peptide, plasma glucagon, total and active GLP-1, and total and active GIP levels were conducted using blood samples that were drawn at five time points (0, 15, 30, 60, and 120&#x000a0;min) after breakfast following a 14-h overnight fast. Active GLP-1 concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Millipore Corp., Billerica, MA, USA) with solid-phase extraction [<xref ref-type="bibr" rid="CR16">16</xref>]. Total GLP-1 concentrations were measured using a Total GLP-1 (ver. 2) Assay Kit with an electrochemiluminescence (ECL) method (Meso Scale Discovery, Rockville, MD, USA). Active GIP<sub>1&#x02013;42</sub> and inactive GIP<sub>3&#x02013;42</sub> were simultaneously measured using nanoflow liquid chromatography tandem mass spectrometry (LC&#x02013;MS/MS) [<xref ref-type="bibr" rid="CR17">17</xref>]. Total GIP concentration was calculated as the sum of GIP<sub>1&#x02013;42</sub> and GIP<sub>3&#x02013;42</sub> concentrations. All sample measurements, except those for total and active GIP, were performed by Mitsubishi Chemical Medience Corporation (Tokyo, Japan). Total and active GIP were measured by Sanwa Kagaku Kenkyusyo Co., Ltd (Aichi, Japan). Serum C-peptide levels were measured using a chemiluminescent immunoassay (CLIA), and plasma glucagon was measured using a double-antibody radioimmunoassay (RIA). The area under the curve (AUC) values for these hormones after meal ingestion were calculated using the trapezoidal rule.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Case 1</th><th align="left">Case 2</th><th align="left">Case 3</th><th align="left">Case 4</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">63</td><td align="left">80</td><td align="left">77</td><td align="left">83</td></tr><tr><td align="left">Sex</td><td align="left">Male</td><td align="left">Male</td><td align="left">Male</td><td align="left">Female</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">26.2</td><td align="left">26.5</td><td align="left">22.1</td><td align="left">24.8</td></tr><tr><td align="left">Diabetes duration (years)</td><td align="left">8</td><td align="left">15</td><td align="left">22</td><td align="left">8</td></tr><tr><td align="left">HbA1c (%)</td><td align="left">7.1</td><td align="left">8.0</td><td align="left">7.7</td><td align="left">8.7</td></tr><tr><td align="left">24-h urinary C-peptide (&#x003bc;g/day)</td><td align="left">45.2</td><td align="left">36.4</td><td align="left">9.7</td><td align="left">59.8</td></tr><tr><td align="left">OAD use before the study</td><td align="left">Metformin</td><td align="left">&#x003b1;-GI&#x000a0;+&#x000a0;glinide</td><td align="left">&#x003b1;-GI</td><td align="left">None</td></tr><tr><td align="left">Insulin use before the study</td><td align="left">Ins L&#x000a0;+&#x000a0;Ins G</td><td align="left">Ins G</td><td align="left">Ins L&#x000a0;+&#x000a0;Ins G</td><td align="left">Ins G</td></tr><tr><td align="left">OAD use during the study</td><td align="left">Metformin</td><td align="left">None</td><td align="left">None</td><td align="left">None</td></tr><tr><td align="left">Dosage and timing of insulin injection during the study</td><td align="left">Ins G (10 units) before bedtime</td><td align="left">Ins G (5 units) before breakfast</td><td align="left">Ins G (5 units) before lunch</td><td align="left">Ins G (5 units) before bedtime</td></tr></tbody></table><table-wrap-foot><p>
<italic>BMI</italic> body mass index, <italic>HbA1c</italic> glycosylated hemoglobin, <italic>OAD</italic> oral antidiabetic drug, <italic>&#x003b1;-GI</italic> &#x003b1;-glucosidase inhibitor, <italic>Ins L</italic> insulin lispro, <italic>Ins G</italic> insulin glargine</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec3"><title>Outcomes</title><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the representative CGM results of each patient. In case 1, the glucose levels and fluctuations after miglitol administration were not remarkably attenuated but were attenuated when miglitol and anagliptin were coadministered. In case 2, the glucose levels and fluctuations were not remarkably attenuated even after the administration of miglitol alone or coadministration of miglitol and anagliptin. In cases 3 and 4, the glucose levels and fluctuations after miglitol administration were attenuated, and this attenuation was even more pronounced with the combination of miglitol and anagliptin. The accuracy of these measurements was reflected in the mean and standard deviation (SD) values of the CGM measurements (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Continuous glucose monitoring (CGM) results for cases 1&#x02013;4 under the conditions of insulin administration, coadministration of insulin and miglitol, and coadministration of insulin, miglitol, and anagliptin</p></caption><graphic xlink:href="40261_2014_260_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>24-h Glucose levels measured by continuous glucose monitoring (CGM)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Treatment</th><th align="left" colspan="4">Glucose level (mg/dL)</th></tr><tr><th align="left">Case 1</th><th align="left">Case 2</th><th align="left">Case 3</th><th align="left">Case 4</th></tr></thead><tbody><tr><td align="left">Insulin alone</td><td char="&#x000b1;" align="char">176&#x000a0;&#x000b1;&#x000a0;36</td><td char="&#x000b1;" align="char">189&#x000a0;&#x000b1;&#x000a0;42</td><td char="&#x000b1;" align="char">234&#x000a0;&#x000b1;&#x000a0;91</td><td char="&#x000b1;" align="char">261&#x000a0;&#x000b1;&#x000a0;37</td></tr><tr><td align="left">Insulin&#x000a0;+&#x000a0;miglitol</td><td char="&#x000b1;" align="char">184&#x000a0;&#x000b1;&#x000a0;30</td><td char="&#x000b1;" align="char">216&#x000a0;&#x000b1;&#x000a0;52</td><td char="&#x000b1;" align="char">165&#x000a0;&#x000b1;&#x000a0;36</td><td char="&#x000b1;" align="char">220&#x000a0;&#x000b1;&#x000a0;26</td></tr><tr><td align="left">Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="&#x000b1;" align="char">137&#x000a0;&#x000b1;&#x000a0;20</td><td char="&#x000b1;" align="char">208&#x000a0;&#x000b1;&#x000a0;37</td><td char="&#x000b1;" align="char">162&#x000a0;&#x000b1;&#x000a0;27</td><td char="&#x000b1;" align="char">198&#x000a0;&#x000b1;&#x000a0;16</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;SD</p></table-wrap-foot></table-wrap></p><p>The time-course levels of plasma glucose, serum C-peptide, plasma glucagon, total and active GLP-1, and total and active GIP and the AUC values for these hormones for up to 120&#x000a0;min after meal ingestion are summarized in Supplementary Figures&#x000a0;2&#x02013;5 and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Under the fixed dosage and timing of the insulin injection, miglitol administration attenuated the postprandial increments in plasma glucose levels in all of the patients. When anagliptin was coadministered with miglitol, further attenuation of postprandial increments in glucose was observed in case 1, but no remarkable changes in postprandial glucose levels were observed in the other patients. Miglitol administration attenuated the postprandial increments in C-peptide levels in all of the patients. When anagliptin was coadministered with miglitol, compared with the sole administration of miglitol, no remarkable changes in postprandial C-peptide levels were observed in cases 1 and 2, but slight increases were observed in cases 3 and 4 although the C-peptide levels in cases 3 and 4 were much lower than in the other patients. Miglitol administration had no observable effect on blood glucagon levels after meal ingestion in all patients except case 1. When anagliptin was administered in addition to miglitol, compared to miglitol alone, no remarkable changes in glucagon levels were observed in cases 2 and 3, but a reduction in glucagon levels was observed in cases 1 and 4.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Area under the curve (AUC) values during the 120-min meal test</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Case 1</th><th align="left">Case 2</th><th align="left">Case 3</th><th align="left">Case 4</th></tr></thead><tbody><tr><td align="left" colspan="5">Glucose AUC (10<sup>3</sup>&#x000a0;&#x000d7;&#x000a0;mg/dL&#x000b7;120&#x000a0;min)</td></tr><tr><td align="left">&#x000a0;Insulin</td><td char="." align="char">22.2</td><td char="." align="char">31.6</td><td char="." align="char">23.8</td><td char="." align="char">33.9</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol</td><td char="." align="char">18.9</td><td char="." align="char">24.4</td><td char="." align="char">14.7</td><td char="." align="char">22.2</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="." align="char">15.3</td><td char="." align="char">24.0</td><td char="." align="char">14.6</td><td char="." align="char">25.8</td></tr><tr><td align="left" colspan="5">C-peptide AUC (nmol/L&#x000b7;120&#x000a0;min)</td></tr><tr><td align="left">&#x000a0;Insulin</td><td char="." align="char">132.4</td><td char="." align="char">109.5</td><td char="." align="char">35.5</td><td char="." align="char">67.3</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol</td><td char="." align="char">93.6</td><td char="." align="char">86.1</td><td char="." align="char">16.9</td><td char="." align="char">42.5</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="." align="char">92.1</td><td char="." align="char">88.6</td><td char="." align="char">24.6</td><td char="." align="char">61.3</td></tr><tr><td align="left" colspan="5">Glucagon AUC (10<sup>3</sup>&#x000a0;&#x000d7;&#x000a0;ng/L&#x000b7;120&#x000a0;min)</td></tr><tr><td align="left">&#x000a0;Insulin</td><td char="." align="char">17.5</td><td char="." align="char">17.3</td><td char="." align="char">12.4</td><td char="." align="char">11.9</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol</td><td char="." align="char">15.4</td><td char="." align="char">16.8</td><td char="." align="char">13.0</td><td char="." align="char">12.3</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="." align="char">13.7</td><td char="." align="char">18.4</td><td char="." align="char">11.8</td><td char="." align="char">10.8</td></tr><tr><td align="left" colspan="5">Total GLP-1 (10<sup>2</sup>&#x000a0;&#x000d7;&#x000a0;pmol/L&#x000b7;120&#x000a0;min)</td></tr><tr><td align="left">&#x000a0;Insulin</td><td char="." align="char">26.8</td><td char="." align="char">29.9</td><td char="." align="char">7.3</td><td char="." align="char">14.4</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol</td><td char="." align="char">21.4</td><td char="." align="char">19.8</td><td char="." align="char">11.6</td><td char="." align="char">16.9</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="." align="char">22.1</td><td char="." align="char">29.3</td><td char="." align="char">9.9</td><td char="." align="char">17.0</td></tr><tr><td align="left" colspan="5">Active GLP-1 (10<sup>2</sup>&#x000a0;&#x000d7;&#x000a0;pmol/L&#x000b7;120&#x000a0;min)</td></tr><tr><td align="left">&#x000a0;Insulin</td><td char="." align="char">5.1</td><td char="." align="char">3.5</td><td char="." align="char">1.4</td><td char="." align="char">3.2</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol</td><td char="." align="char">3.1</td><td char="." align="char">1.9</td><td char="." align="char">1.4</td><td char="." align="char">3.6</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="." align="char">8.7</td><td char="." align="char">10.7</td><td char="." align="char">2.5</td><td char="." align="char">6.8</td></tr><tr><td align="left" colspan="5">Total GIP (10<sup>2</sup>&#x000a0;&#x000d7;&#x000a0;pmoL/L&#x000b7;120&#x000a0;min)</td></tr><tr><td align="left">&#x000a0;Insulin</td><td char="." align="char">278.6</td><td char="." align="char">318.2</td><td char="." align="char">131.7</td><td char="." align="char">73.0</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol</td><td char="." align="char">92.0</td><td char="." align="char">120.5</td><td char="." align="char">58.6</td><td char="." align="char">61.6</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="." align="char">150.7</td><td char="." align="char">73.6</td><td char="." align="char">28.6</td><td char="." align="char">37.7</td></tr><tr><td align="left" colspan="5">Active GIP (10<sup>2</sup>&#x000a0;&#x000d7;&#x000a0;pmol/L&#x000b7;120&#x000a0;min)</td></tr><tr><td align="left">&#x000a0;Insulin</td><td char="." align="char">109.6</td><td char="." align="char">60.0</td><td char="." align="char">31.9</td><td char="." align="char">31.0</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol</td><td char="." align="char">19.2</td><td char="." align="char">24.2</td><td char="." align="char">8.4</td><td char="." align="char">8.1</td></tr><tr><td align="left">&#x000a0;Insulin&#x000a0;+&#x000a0;miglitol&#x000a0;+&#x000a0;anagliptin</td><td char="." align="char">97.5</td><td char="." align="char">44.0</td><td char="." align="char">9.8</td><td char="." align="char">18.1</td></tr></tbody></table><table-wrap-foot><p>
<italic>GLP-1</italic> glucagon-like peptide-1, <italic>GIP</italic> glucose-dependent insulinotropic polypeptide</p></table-wrap-foot></table-wrap></p><p>Miglitol administration decreased active GLP-1 levels in cases 1 and 2, but not in cases 3 and 4. However, when anagliptin was administered in addition to miglitol, all of the patients showed increased active GLP-1 levels compared to when miglitol alone was added. The AUC values for active GLP-1 with the coadministration of miglitol and anagliptin tended to be larger than the AUC values for active GLP-1 when miglitol alone was added (<italic>p</italic>&#x000a0;=&#x000a0;0.07; Wilcoxon signed-rank test). Miglitol administration showed remarkable reductions in active GIP levels in all patients. Compared to when miglitol alone was added, coadministration of miglitol and anagliptin showed higher active GIP levels in all patients, with varying patterns. The active:total GLP-1 ratio and active:total GIP ratio in each patient are shown in Supplementary Figures&#x000a0;6 and 7, respectively. Miglitol administration showed lower or at least similar active:total GLP-1 ratios and active:total GIP ratios in all patients, whereas coadministration of miglitol and anagliptin showed remarkably higher active:total GLP-1 ratios and active:total GIP ratios in all patients.</p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>In the present study, administration of miglitol to four patients with type 2 diabetes receiving ongoing insulin treatment showed beneficial effects on postprandial hyperglycemia. Based on the CGM results, the coadministration of anagliptin with miglitol resulted in additional improvements in glycemic control over the entire day in three of the patients, including lower glucose levels and attenuated glucose fluctuations. In addition, administration of only miglitol or in combination with anagliptin reduced postprandial C-peptide levels in all patients we studied, which might be explained by the associated decrease in blood glucose levels. The reason underlying the lack of a further effect on glycemic control with anagliptin co-administration in case 2 is not clear. A previous study conducted in Japanese patients with type 2 diabetes indicated that treatment with a different DPP-4 inhibitor, sitagliptin, lowered glycosylated hemoglobin (HbA1c) levels, especially in those with higher baseline HbA1c levels, lower body mass indices (BMIs), and shorter durations of diabetes [<xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, the combination of a high HbA1c level, relatively high BMI, and long history of diabetes in case 2 may have affected the efficacy of anagliptin in this patient to some extent.</p><p>Regarding glucagon levels, the effect of miglitol-only administration was varied; however, when anagliptin was coadministered with miglitol, all of the patients, except case 2, showed a tendency for suppressed glucagon secretion. Theoretically, DPP-4 inhibitors, including anagliptin, increase GLP-1 levels, and GLP-1 lowers glucose levels not only by its potent insulinotropic action but also by its ability to suppress glucagon secretion [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. It remains uncertain and controversial whether GLP-1 directly suppresses glucagon release by binding to GLP-1 receptors expressed on the alpha cell [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Indirectly, other intraislet paracrine factors, including insulin [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], somatostatin [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], &#x003b3;-aminobutyric acid (GABA) [<xref ref-type="bibr" rid="CR27">27</xref>], and zinc ions (Zn) [<xref ref-type="bibr" rid="CR28">28</xref>], are considered to modulate glucagon secretion. In addition, a recent report suggested that increased portal GLP-1 levels activate brain-derived neurotrophic factor (BDNF) and BDNF modulates glucagon secretion from pancreatic &#x003b1; cells via the central and peripheral nervous systems [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>In patients with diabetes, miglitol is also reported to induce enhanced and prolonged GLP-1 release after meal ingestion [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. A possible mechanism may be increased exposure of nutrients to the distal small intestine, where L-cells are located [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. To confirm these results, we previously studied postprandial active GLP-1 levels in patients with type 2 diabetes treated with or without insulin and found that miglitol administration increased active GLP-1 levels in some, but not all, patients [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The effect of miglitol administration in the present study resulted in varying total or active GLP-1 levels in each patient, but no typical pattern was observed. As we expected, coadministration of miglitol and anagliptin showed increased postprandial active GLP-1 levels in all patients of various magnitudes, reflecting the pharmacologic effect of anagliptin as a DPP-4 inhibitor. Despite increased active GLP-1 levels, an increase in total GLP-1 levels was not observed in all patients.</p><p>Miglitol administration is reported to decrease GIP levels, possibly via inhibited glucose absorption in the proximal small intestine [<xref ref-type="bibr" rid="CR34">34</xref>]. Our results are consistent with this theory. Compared to miglitol administration alone, the coadministration of miglitol and anagliptin showed increased active GIP levels in all of our patients, reflecting the pharmacologic effect of anagliptin as a DPP-4 inhibitor; however, there was a decrease in total GIP levels in all patients, except case 1. As previously suggested, this phenomenon may be explained by a feedback inhibitory mechanism; the elevated concentrations of endogenous biologic active (intact) forms of the incretins may themselves restrict further secretion from the K- and L-cells [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p>In cases 1 and 2, both total and active GIP levels were higher than in the other patients, even before anagliptin administration. The BMIs of these patients were also higher than the other patients. It is well known that GIP promotes the efficient storage of ingested fat and directly links overnutrition to obesity [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Furthermore, recent research suggests that GIP receptor antagonists may offer a new therapeutic option for obesity in diabetes [<xref ref-type="bibr" rid="CR41">41</xref>]. As we only examined four patients, our results do not necessarily generalize to the majority of the patients with type 2 diabetes. Therefore, further studies with larger samples are needed.</p></sec><sec id="Sec5" sec-type="conclusion"><title>Conclusion</title><p>Through the use of CGMS, we determined that a combination of &#x003b1;-GI, miglitol, and a DPP-4 inhibitor, anagliptin, was effective in reducing glucose fluctuations and stabilizing postprandial blood glucose levels in three of the four patients. Furthermore, C-peptide, glucagon, and total and active GLP-1 and GIP responded differently to the study medications for each patient, suggesting that hormonal responses to these drugs differ among individuals and may be complicated by multifactorial effects. Another larger study is needed to confirm the associations observed in our patients.
</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec6"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40261_2014_260_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 14 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40261_2014_260_MOESM2_ESM.pdf"><caption><p>Supplementary material 2 (PDF 263 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="40261_2014_260_MOESM3_ESM.pdf"><caption><p>Supplementary material 3 (PDF 277 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="40261_2014_260_MOESM4_ESM.pdf"><caption><p>Supplementary material 4 (PDF 250 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="40261_2014_260_MOESM5_ESM.pdf"><caption><p>Supplementary material 5 (PDF 259 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="40261_2014_260_MOESM6_ESM.pdf"><caption><p>Supplementary material 6 (PDF 190 kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="40261_2014_260_MOESM7_ESM.pdf"><caption><p>Supplementary material 7 (PDF 194 kb)</p></caption></media></supplementary-material></sec></sec></body><back><ack><p>Miyako Kishimoto has received a grant from the Joint Research Association for Japanese Diabetes. Mitsuhiko Noda has received speaker honoraria from Sanofi, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Eli Lilly Japan, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Sanwa Kagaku Kenkyusho, Asahi Kasei Pharma, Ono Pharmaceutical Co. LTD., Takeda Pharmaceutical Co. LTD., Astellas, Kowa Pharmaceutical Co. LTD., Terumo Corporation, Taisho Toyama Pharmaceutical Co. LTD., Kissei Pharmaceutical Co. LTD. and Mochida Pharmaceutical Co. LTD.; and research grants from Takeda Pharmaceutical Co. LTD., Daiichi Sankyo, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co. LTD., Sanwa Kagaku Kenkyusho, Kowa Pharmaceutical Co. LTD., Sumitomo Dainippon Pharma, Novartis Pharma, Sanofi, Teijin and AstraZeneca.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karasik</surname><given-names>A</given-names></name><name><surname>Aschner</surname><given-names>P</given-names></name><name><surname>Katzeff</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Stein</surname><given-names>PP</given-names></name></person-group><article-title>Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials</article-title><source>Curr Med Res Opin.</source><year>2008</year><volume>24</volume><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1185/030079908X261069</pub-id><pub-id pub-id-type="pmid">18182122</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Man</surname><given-names>CD</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach</article-title><source>Diabetes Obes Metab.</source><year>2008</year><volume>10</volume><fpage>1212</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">18476982</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazg</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Dalla Man</surname><given-names>C</given-names></name><name><surname>Cobelli</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>K</given-names></name><name><surname>Stein</surname><given-names>PP</given-names></name></person-group><article-title>Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes</article-title><source>Diabetes Obes Metab.</source><year>2007</year><volume>9</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2006.00691.x</pub-id><pub-id pub-id-type="pmid">17300594</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1696</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69705-5</pub-id><pub-id pub-id-type="pmid">17098089</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>GA</given-names></name><name><surname>Bergman</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes</article-title><source>J Clin Endocrinol Metab.</source><year>2006</year><volume>91</volume><fpage>4612</fpage><lpage>4619</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-1009</pub-id><pub-id pub-id-type="pmid">16912128</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>M</given-names></name></person-group><article-title>Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes</article-title><source>Diabetes Metab Syndr Obes.</source><year>2013</year><volume>6</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.2147/DMSO.S35682</pub-id><pub-id pub-id-type="pmid">23671395</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ</given-names></name></person-group><article-title>Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?</article-title><source>Drugs</source><year>2003</year><volume>63</volume><fpage>933</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.2165/00003495-200363100-00002</pub-id><pub-id pub-id-type="pmid">12699398</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>H</given-names></name></person-group><article-title>Pharmacology of alpha-glucosidase inhibition</article-title><source>Eur J Clin Invest.</source><year>1994</year><volume>24</volume><issue>Suppl 3</issue><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">8001624</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Spencer</surname><given-names>CM</given-names></name></person-group><article-title>Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus</article-title><source>Drugs</source><year>2000</year><volume>59</volume><fpage>521</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.2165/00003495-200059030-00012</pub-id><pub-id pub-id-type="pmid">10776834</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name></person-group><article-title>A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers</article-title><source>Cardiovasc Diabetol.</source><year>2011</year><volume>10</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-10-115</pub-id><pub-id pub-id-type="pmid">22189184</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name></person-group><article-title>Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes</article-title><source>Diabetes Ther.</source><year>2012</year><volume>3</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1007/s13300-012-0011-x</pub-id><pub-id pub-id-type="pmid">23055336</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>TM</given-names></name><name><surname>Bode</surname><given-names>BW</given-names></name><name><surname>Einhorn</surname><given-names>D</given-names></name><etal/></person-group><article-title>Performance evaluation of the MiniMed Continuous Glucose Monitoring System during patient home use</article-title><source>Diabetes Technol Ther.</source><year>2000</year><volume>2</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1089/152091500316737</pub-id><pub-id pub-id-type="pmid">11467320</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>FR</given-names></name><name><surname>Gibson</surname><given-names>LC</given-names></name><name><surname>Halvorson</surname><given-names>M</given-names></name><name><surname>Carpenter</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>LK</given-names></name><name><surname>Pitukcheewanont</surname><given-names>P</given-names></name></person-group><article-title>A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects</article-title><source>Diabetes Care.</source><year>2001</year><volume>24</volume><fpage>2030</fpage><lpage>2034</lpage><pub-id pub-id-type="doi">10.2337/diacare.24.12.2030</pub-id><pub-id pub-id-type="pmid">11723078</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachedina</surname><given-names>N</given-names></name><name><surname>Pickup</surname><given-names>JC</given-names></name></person-group><article-title>Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in type 1 diabetic subjects</article-title><source>Diabet Med.</source><year>2003</year><volume>20</volume><fpage>1012</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1046/j.1464-5491.2003.01037.x</pub-id><pub-id pub-id-type="pmid">14632702</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>N</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name><name><surname>Murase</surname><given-names>T</given-names></name><etal/></person-group><article-title>Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor</article-title><source>Bioorg Med Chem.</source><year>2011</year><volume>19</volume><fpage>7221</fpage><lpage>7227</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2011.09.043</pub-id><pub-id pub-id-type="pmid">22019046</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yabe</surname><given-names>D</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Sugawara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes</article-title><source>J Diabetes Invest.</source><year>2012</year><volume>3</volume><fpage>70</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/j.2040-1124.2011.00141.x</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyachi</surname><given-names>A</given-names></name><name><surname>Murase</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Osonoi</surname><given-names>T</given-names></name><name><surname>Harada</surname><given-names>K</given-names></name></person-group><article-title>Quantitative analytical method for determining the levels of gastric inhibitory polypeptides GIP1-42 and GIP3-42 in human plasma using LC&#x02013;MS/MS/MS</article-title><source>J Proteome Res</source><year>2013</year><volume>12</volume><fpage>2690</fpage><lpage>2699</lpage><pub-id pub-id-type="doi">10.1021/pr400069f</pub-id><pub-id pub-id-type="pmid">23607762</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomiyama</surname><given-names>T</given-names></name><name><surname>Akehi</surname><given-names>Y</given-names></name><name><surname>Takenoshita</surname><given-names>H</given-names></name><etal/></person-group><article-title>Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes</article-title><source>Diabetes Res Clin Pract.</source><year>2012</year><volume>95</volume><fpage>e27</fpage><lpage>e28</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2011.08.016</pub-id><pub-id pub-id-type="pmid">21899912</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Heer</surname><given-names>J</given-names></name><name><surname>Rasmussen</surname><given-names>C</given-names></name><name><surname>Coy</surname><given-names>DH</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>2263</fpage><lpage>2270</lpage><pub-id pub-id-type="doi">10.1007/s00125-008-1149-y</pub-id><pub-id pub-id-type="pmid">18795252</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name></person-group><article-title>Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men</article-title><source>Endocrine J.</source><year>2010</year><volume>57</volume><fpage>667</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K10E-103</pub-id><pub-id pub-id-type="pmid">20519806</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bock</surname><given-names>G</given-names></name><name><surname>DallaMan</surname><given-names>C</given-names></name><name><surname>Micheletto</surname><given-names>F</given-names></name><etal/></person-group><article-title>The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose</article-title><source>Clin Endocrinol.</source><year>2010</year><volume>73</volume><fpage>189</fpage><lpage>196</lpage></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Marinis</surname><given-names>YZ</given-names></name><name><surname>Salehi</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>CE</given-names></name><etal/></person-group><article-title>GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis</article-title><source>Cell Metab.</source><year>2010</year><volume>11</volume><fpage>543</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2010.04.007</pub-id><pub-id pub-id-type="pmid">20519125</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Hisatomi</surname><given-names>A</given-names></name><name><surname>Orci</surname><given-names>L</given-names></name><name><surname>Grodsky</surname><given-names>GM</given-names></name><name><surname>Unger</surname><given-names>RH</given-names></name></person-group><article-title>Insulin within islets is a physiologic glucagon release inhibitor</article-title><source>J Clin Invest.</source><year>1984</year><volume>74</volume><fpage>2296</fpage><lpage>2299</lpage><pub-id pub-id-type="doi">10.1172/JCI111658</pub-id><pub-id pub-id-type="pmid">6392344</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamori</surname><given-names>D</given-names></name><name><surname>Kurpad</surname><given-names>AJ</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Insulin signaling in alpha cells modulates glucagon secretion in vivo</article-title><source>Cell Metab.</source><year>2009</year><volume>9</volume><fpage>350</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2009.02.007</pub-id><pub-id pub-id-type="pmid">19356716</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Christensen</surname><given-names>M</given-names></name><name><surname>Lund</surname><given-names>A</given-names></name><etal/></person-group><article-title>Regulation of glucagon secretion by incretins</article-title><source>Diabetes Obes Metab.</source><year>2011</year><volume>13</volume><issue>Suppl 1</issue><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01452.x</pub-id><pub-id pub-id-type="pmid">21824261</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cejvan</surname><given-names>K</given-names></name><name><surname>Coy</surname><given-names>DH</given-names></name><name><surname>Efendic</surname><given-names>S</given-names></name></person-group><article-title>Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>1176</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.5.1176</pub-id><pub-id pub-id-type="pmid">12716749</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rorsman</surname><given-names>P</given-names></name><name><surname>Berggren</surname><given-names>PO</given-names></name><name><surname>Bokvist</surname><given-names>K</given-names></name><etal/></person-group><article-title>Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels</article-title><source>Nature</source><year>1989</year><volume>341</volume><fpage>233</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/341233a0</pub-id><pub-id pub-id-type="pmid">2550826</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>H</given-names></name><name><surname>Maechler</surname><given-names>P</given-names></name><name><surname>Gjinovci</surname><given-names>A</given-names></name><name><surname>Herrera</surname><given-names>PL</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name></person-group><article-title>Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells</article-title><source>Nat Cell Biol</source><year>2003</year><volume>5</volume><fpage>330</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/ncb951</pub-id><pub-id pub-id-type="pmid">12640462</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>K</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hypothalamic brain-derived neurotrophic factor regulates glucagon secretion mediated by pancreatic efferent nerves</article-title><source>J Neuroendocrinol.</source><year>2013</year><volume>25</volume><fpage>302</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1111/jne.12003</pub-id><pub-id pub-id-type="pmid">23157205</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name></person-group><article-title>Physiology of incretins in health and disease</article-title><source>Rev Diabet Stud.</source><year>2011</year><volume>8</volume><fpage>293</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1900/RDS.2011.8.293</pub-id><pub-id pub-id-type="pmid">22262068</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranganath</surname><given-names>L</given-names></name><name><surname>Norris</surname><given-names>F</given-names></name><name><surname>Morgan</surname><given-names>L</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Marks</surname><given-names>V</given-names></name></person-group><article-title>Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect</article-title><source>Diabet Med.</source><year>1998</year><volume>15</volume><fpage>120</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9136(199802)15:2&#x0003c;120::AID-DIA529&#x0003e;3.0.CO;2-I</pub-id><pub-id pub-id-type="pmid">9507911</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Patrick</surname><given-names>P</given-names></name><name><surname>Wishart</surname><given-names>J</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name></person-group><article-title>The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics</article-title><source>Diabetes Obes Metab.</source><year>2002</year><volume>4</volume><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1046/j.1463-1326.2002.00219.x</pub-id><pub-id pub-id-type="pmid">12190996</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Kamiyama</surname><given-names>H</given-names></name><name><surname>Yoshimura</surname><given-names>K</given-names></name><name><surname>Shibuya</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name></person-group><article-title>Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin</article-title><source>Acta Diabetol.</source><year>2012</year><volume>49</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1007/s00592-011-0322-9</pub-id><pub-id pub-id-type="pmid">21898126</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>T</given-names></name><name><surname>Katsuura</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><etal/></person-group><article-title>Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients</article-title><source>Diabet Med.</source><year>2009</year><volume>26</volume><fpage>187</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2008.02651.x</pub-id><pub-id pub-id-type="pmid">19236625</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparison of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>283</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01526.x</pub-id><pub-id pub-id-type="pmid">22051162</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qualmann</surname><given-names>C</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group><article-title>Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)</article-title><source>Scand J Gastroenterol.</source><year>1995</year><volume>30</volume><fpage>892</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.3109/00365529509101597</pub-id><pub-id pub-id-type="pmid">8578189</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Wamberg</surname><given-names>S</given-names></name><name><surname>Bie</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>TE</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs</article-title><source>J Endocrinol.</source><year>2002</year><volume>172</volume><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1677/joe.0.1720355</pub-id><pub-id pub-id-type="pmid">11834453</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyawaki</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Ban</surname><given-names>N</given-names></name><etal/></person-group><article-title>Inhibition of gastric inhibitory polypeptide signaling prevents obesity</article-title><source>Nat Med.</source><year>2002</year><volume>8</volume><fpage>738</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1038/nm727</pub-id><pub-id pub-id-type="pmid">12068290</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>E</given-names></name><name><surname>Katsuno</surname><given-names>T</given-names></name><name><surname>Miyagawa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus</article-title><source>Endocr J.</source><year>2011</year><volume>58</volume><fpage>869</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K11E-129</pub-id><pub-id pub-id-type="pmid">21869539</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Miyawaki</surname><given-names>K</given-names></name><name><surname>Tsukiyama</surname><given-names>K</given-names></name><name><surname>Harada</surname><given-names>N</given-names></name><name><surname>Yamada</surname><given-names>C</given-names></name><name><surname>Seino</surname><given-names>Y</given-names></name></person-group><article-title>Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>S86</fpage><lpage>S91</lpage><pub-id pub-id-type="doi">10.2337/db06-S011</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>N</given-names></name><name><surname>Flatt</surname><given-names>PR</given-names></name></person-group><article-title>Therapeutic potential for GIP receptor agonists and antagonists</article-title><source>Best Pract Res Clin Endocrinol Metab.</source><year>2009</year><volume>23</volume><fpage>499</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2009.03.001</pub-id><pub-id pub-id-type="pmid">19748067</pub-id></element-citation></ref></ref-list></back></article>